QQQ   432.22 (+0.27%)
AAPL   169.35 (-1.93%)
MSFT   416.39 (+0.66%)
META   502.86 (+0.53%)
GOOGL   154.69 (-0.11%)
AMZN   184.02 (+0.22%)
TSLA   157.92 (-2.20%)
NVDA   875.30 (+1.78%)
AMD   163.71 (+2.11%)
NIO   3.84 (-1.29%)
BABA   70.00 (-0.88%)
T   16.07 (-1.05%)
F   12.19 (-0.33%)
MU   121.40 (+0.02%)
GE   155.60 (+1.24%)
CGC   6.89 (-1.29%)
DIS   114.10 (+1.02%)
AMC   2.73 (+10.53%)
PFE   25.86 (-0.19%)
PYPL   63.99 (+0.76%)
XOM   118.92 (-0.64%)
QQQ   432.22 (+0.27%)
AAPL   169.35 (-1.93%)
MSFT   416.39 (+0.66%)
META   502.86 (+0.53%)
GOOGL   154.69 (-0.11%)
AMZN   184.02 (+0.22%)
TSLA   157.92 (-2.20%)
NVDA   875.30 (+1.78%)
AMD   163.71 (+2.11%)
NIO   3.84 (-1.29%)
BABA   70.00 (-0.88%)
T   16.07 (-1.05%)
F   12.19 (-0.33%)
MU   121.40 (+0.02%)
GE   155.60 (+1.24%)
CGC   6.89 (-1.29%)
DIS   114.10 (+1.02%)
AMC   2.73 (+10.53%)
PFE   25.86 (-0.19%)
PYPL   63.99 (+0.76%)
XOM   118.92 (-0.64%)
QQQ   432.22 (+0.27%)
AAPL   169.35 (-1.93%)
MSFT   416.39 (+0.66%)
META   502.86 (+0.53%)
GOOGL   154.69 (-0.11%)
AMZN   184.02 (+0.22%)
TSLA   157.92 (-2.20%)
NVDA   875.30 (+1.78%)
AMD   163.71 (+2.11%)
NIO   3.84 (-1.29%)
BABA   70.00 (-0.88%)
T   16.07 (-1.05%)
F   12.19 (-0.33%)
MU   121.40 (+0.02%)
GE   155.60 (+1.24%)
CGC   6.89 (-1.29%)
DIS   114.10 (+1.02%)
AMC   2.73 (+10.53%)
PFE   25.86 (-0.19%)
PYPL   63.99 (+0.76%)
XOM   118.92 (-0.64%)
QQQ   432.22 (+0.27%)
AAPL   169.35 (-1.93%)
MSFT   416.39 (+0.66%)
META   502.86 (+0.53%)
GOOGL   154.69 (-0.11%)
AMZN   184.02 (+0.22%)
TSLA   157.92 (-2.20%)
NVDA   875.30 (+1.78%)
AMD   163.71 (+2.11%)
NIO   3.84 (-1.29%)
BABA   70.00 (-0.88%)
T   16.07 (-1.05%)
F   12.19 (-0.33%)
MU   121.40 (+0.02%)
GE   155.60 (+1.24%)
CGC   6.89 (-1.29%)
DIS   114.10 (+1.02%)
AMC   2.73 (+10.53%)
PFE   25.86 (-0.19%)
PYPL   63.99 (+0.76%)
XOM   118.92 (-0.64%)
NASDAQ:EDIT

Editas Medicine (EDIT) Stock Price, News & Analysis

$5.95
-0.13 (-2.14%)
(As of 12:52 PM ET)
Today's Range
$5.89
$6.03
50-Day Range
$6.08
$11.07
52-Week Range
$5.89
$11.91
Volume
472,089 shs
Average Volume
1.81 million shs
Market Capitalization
$486.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Editas Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
150.8% Upside
$15.00 Price Target
Short Interest
Bearish
20.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.67mentions of Editas Medicine in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$924,582 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.61) to ($2.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.54 out of 5 stars

Medical Sector

277th out of 930 stocks

Biological Products, Except Diagnostic Industry

37th out of 155 stocks

EDIT stock logo

About Editas Medicine Stock (NASDAQ:EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock Price History

EDIT Stock News Headlines

AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Q4 2023 Editas Medicine Inc Earnings Call
Here's what Wall Street expects from Editas Medicine's earnings report
Earnings Outlook For Editas Medicine
Editas Medicine Q4 2023 Earnings Preview
EDIT Mar 2024 7.000 put
EDIT Mar 2024 12.000 call
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/16/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
265
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+146.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-153,220,000.00
Net Margins
-196.12%
Pretax Margin
-196.12%

Debt

Sales & Book Value

Annual Sales
$78.12 million
Book Value
$4.27 per share

Miscellaneous

Free Float
80,014,000
Market Cap
$497.40 million
Optionable
Optionable
Beta
2.02
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Gilmore O'Neill M.D. (Age 59)
    President, CEO & Director
    Comp: $815.37k
  • Dr. Baisong Mei M.D.
    Ph.D., Senior VP & Chief Medical Officer
  • Dr. Feng Zhang Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D. (Age 70)
    Co-Founder & Scientific Advisory Board Member
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Erick J. Lucera C.F.A. (Age 56)
    CPA, CFO & Executive VP
  • Dr. Linda C. Burkly Ph.D.
    Executive VP & Chief Scientific Officer
  • Cristi Barnett
    Corporate Communications & Investor Relations
  • Ms. Charlene Stern J.D.
    Ph.D., Executive VP & General Counsel

EDIT Stock Analysis - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price target for 2024?

9 Wall Street analysts have issued 1 year price targets for Editas Medicine's stock. Their EDIT share price targets range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 150.8% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2024?

Editas Medicine's stock was trading at $10.13 at the start of the year. Since then, EDIT shares have decreased by 41.0% and is now trading at $5.98.
View the best growth stocks for 2024 here
.

Are investors shorting Editas Medicine?

Editas Medicine saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is currently 8.9 days.
View Editas Medicine's Short Interest
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.29. The business earned $60 million during the quarter, compared to the consensus estimate of $4.84 million. Editas Medicine had a negative trailing twelve-month return on equity of 42.95% and a negative net margin of 196.12%. Editas Medicine's revenue for the quarter was up 817.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.88) earnings per share.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

Editas Medicine (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDIT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners